<DOC>
	<DOC>NCT02093923</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic profile of multiple subcutaneous administrations of DX-2930 across a range of doses in Hereditary Angioedema subjects.</brief_summary>
	<brief_title>Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema (HAE) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<criteria>At least 18 years of age at the time of screening. Documented diagnosis of HAE (Type I or II) Experiencing â‰¥2 HAE attacks per year, with at least 1 attack in the past 6 months reported by the subject. Willing and able to read, understand, and sign an informed consent form. Females of childbearing potential must agree to be abstinent or else use acceptable forms of contraception throughout study Males with female partners of childbearing potential must agree to be abstinent or use a medically acceptable form of contraception throughout study. Exposure to an investigational drug or device within 90 days prior to study. History of exposure within the past 5 years to a monoclonal antibody or recombinant protein bearing an Fc domain. Concomitant diagnosis of another form of chronic angioedema Use of longterm prophylaxis for HAE within 90 days prior to study. Use of C1INH that exceeds a total of 30 days within the past 90 days prior to study; any use of C1INH within 7 days prior to study. Exposure to angiotensinconverting enzyme (ACE) inhibitors or any estrogencontaining medications with systemic absorption within 90 days prior to study. Exposure to androgens within 90 days prior to study. Presence of an indwelling catheter. Diagnosis of HIV. Active liver disease or liver function test abnormalities History of substance abuse or dependence. Pregnancy or breastfeeding. Any condition that, in the opinion of the Investigator, may compromise their safety or compliance, preclude successful conduct of the study, or interfere with interpretation of the results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HAE</keyword>
</DOC>